Johnson & Johnson: completes acquisition of Actelion.
(CercleFinance.com) - Johnson & Johnson has completed its 30-billion-dollar acquisition of Swiss biotech group Actelion, the U.
S. healthcare giant said on Friday.
The acquisition was completed through an all-cash public tender offer by Johnson & Johnson's Swiss subsidiary, Janssen Holding, to acquire all the shares of Actelion.
Actelion will now become part of the Janssen Pharmaceutical unit of Johnson & Johnson.
In a statement, J&J says it expects the transaction to add approximately 1.3 billion dollars in sales for 2017 and be accretive to adjusted earnings per share in 2017.
In connection with the transaction, Actelion has spun off its drug discovery operations and early-stage clinical development assets into a newly created Swiss biopharmaceutical company, Idorsia.
Shares of Idorsia were distributed to Actelion's shareholders as a stock dividend and will begin trading on the SIX Swiss Exchange today.
As previously announced, a subsidiary of Johnson & Johnson will initially hold 9.9 per cent of the shares of Idorsia, with the right to buy an additional 22.1 per cent.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
S. healthcare giant said on Friday.
The acquisition was completed through an all-cash public tender offer by Johnson & Johnson's Swiss subsidiary, Janssen Holding, to acquire all the shares of Actelion.
Actelion will now become part of the Janssen Pharmaceutical unit of Johnson & Johnson.
In a statement, J&J says it expects the transaction to add approximately 1.3 billion dollars in sales for 2017 and be accretive to adjusted earnings per share in 2017.
In connection with the transaction, Actelion has spun off its drug discovery operations and early-stage clinical development assets into a newly created Swiss biopharmaceutical company, Idorsia.
Shares of Idorsia were distributed to Actelion's shareholders as a stock dividend and will begin trading on the SIX Swiss Exchange today.
As previously announced, a subsidiary of Johnson & Johnson will initially hold 9.9 per cent of the shares of Idorsia, with the right to buy an additional 22.1 per cent.
Copyright (c) 2017 CercleFinance.com. All rights reserved.